ABSTRACT
Introduction The median age for breast cancer diagnosis in Europe and in the United States is approximately 65 years. The incidence increases with increasing age.
Major limitations in defining treatment strategies in elderly breast cancer patients are the small volume of data coming from clinical trials and the heterogeneity of the older population, compounded by minimal available data for the treatment of unfit patients. There is increasing agreement that tumor biology, not chronological age, should drive treatment decisions in healthy women with breast cancer.
